Upstream Bio (NASDAQ:UPB) Now Covered by Analysts at Piper Sandler

Investment analysts at Piper Sandler began coverage on shares of Upstream Bio (NASDAQ:UPB) in a research note issued on Tuesday, Briefing.com reports. The brokerage set an “overweight” rating and a $75.00 price target on the stock. Piper Sandler’s price objective points to a potential upside of 198.21% from the company’s previous close.

A number of other research analysts have also recently commented on the stock. William Blair initiated coverage on shares of Upstream Bio in a report on Tuesday. They issued an “outperform” rating for the company. JPMorgan Chase & Co. began coverage on shares of Upstream Bio in a research report on Tuesday. They issued an “overweight” rating and a $38.00 target price on the stock. Finally, TD Cowen began coverage on Upstream Bio in a report on Tuesday. They set a “buy” rating on the stock.

Upstream Bio Price Performance

Shares of NASDAQ:UPB opened at $25.15 on Tuesday. Upstream Bio has a 1 year low of $20.74 and a 1 year high of $27.68.

Insider Activity

In related news, major shareholder Ai Upstream Llc bought 1,175,000 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was acquired at an average cost of $17.00 per share, with a total value of $19,975,000.00. Following the transaction, the insider now directly owns 1,175,000 shares in the company, valued at approximately $19,975,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, major shareholder Ai Upstream Llc purchased 1,175,000 shares of the company’s stock in a transaction dated Tuesday, October 15th. The shares were purchased at an average price of $17.00 per share, for a total transaction of $19,975,000.00. Following the transaction, the insider now owns 1,175,000 shares of the company’s stock, valued at approximately $19,975,000. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Erez Chimovits purchased 825,000 shares of the firm’s stock in a transaction on Tuesday, October 15th. The shares were acquired at an average price of $17.00 per share, with a total value of $14,025,000.00. Following the completion of the acquisition, the director now owns 4,554,873 shares in the company, valued at approximately $77,432,841. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

Upstream Bio Company Profile

Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.